Read More: Novo Says Priority Is Obesity Despite Investor Calls to Expand Doustdar, who took on his current role nearly a year ago, said Novo is increasingly asking its scientists to look beyond weight loss and identify what other diseases future generations of GLP-1 drugs could be designed to remedy
Research on short-term lifestyle programs found that participants generally lost about 6 more pounds over a few months than people who didnt take part, which shows that steady progress can add up faster than many people expect
GLP-1 receptor agonists have also shown success in other therapeutic areas apart from type 2 diabetes and obesity, in particular for non-alcoholic fatty liver disease [104]
Though we do not have studies on exactly how BPC-157 works in humans, laboratory and animal studies suggest that BPC-157 supports the bodys natural healing response through several mechanisms
received an honorarium from Eli Lilly to deliver a talk at the 2025 BOMSS scientific meeting
Bydureon BCise (exenatide ER) A weekly injection, generally considered less potent than newer medications like semaglutide